iECURE, Inc.

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a

Precision BioSciences , which had hoped to be the first company to bring an allogeneic CAR-T to market, has announced its exit from the field with the sale of its lead asset, azercabtagene zapreleucel

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece

Novartis has unveiled an in vivo gene-editing alliance with Precision BioSciences that aims to develop next-generation therapies for conditions such as sickle cell disease and beta-thalassemia. T